The effects of transferring tumor suppressor gene p16\(^{\text{INK4A}}\) to p16\(^{\text{INK4A}}\)-deleted cancer cells\

Kye Young Lee\(^1\), Chul-Gyu Yoo, Sung Koo Han, Young-Soo Shim and Young Whan Kim

Department of Internal Medicine and Lung Institute, College of Medicine, Seoul National University, Seoul 110-744, Korea; \(^1\)Department of Internal Medicine, College of Medicine, Dankook University, Cheonan 330-715, Korea

**Objectives**: p16 is known to be an important tumor suppressor gene and is also called MTS1 (multiple tumor suppressive gene 1). Especially in the case of non-small cell lung cancer, it was not expressed in more than 70% of cell lines examined. To determine changes in cell-cycle related proteins and the tumorigenic effect, we, therefore, transfected p16\(^{\text{INK4A}}\) gene into lung cancer cell lines.

**Methods**: We transfected p16\(^{\text{INK4A}}\) gene into lung cancer cell lines which do not express p16 protein. We evaluated the effect by clonogenic assay and observed the changes of cell-cycle related proteins.

**Results**: The newly-expressed p16 formed a complex with cdk4, and phosphorylated pRB was decreased, although cyclin D1 and pRB:cyclin D1 complex were unchanged. Clonogenic assay after selection with G418 showed that, in the cell lines transfected with p16, tumorigenicity was significantly less than in the control.

**Conclusion**: These results suggest that the p16\(^{\text{INK4A}}\) gene can be a candidate for gene therapy in cases of NSCLC in which p16\(^{\text{INK4A}}\) gene is inactivated.

**Key Words**: p16\(^{\text{INK4A}}\), lung cancer, gene therapy, cell cycle

---

**INTRODUCTION**

It is clear that in human cancer, including lung cancer, deregulation of cell cycle progression is a hallmark of neoplastic transformation and that genes involved in G1/S transition of the cell cycle are especially frequent targets for mutations. A cell-cycle related protein, the recently identified p16\(^{\text{INK4A}}\) gene product, plays an important role in the negative regulation of the kinase activity of cyclin dependent kinase (cdk) enzymes\(^2\). p16\(^{\text{INK4A}}\) gene is, thus, an important tumor suppressor gene and is also called MTS1 (multiple tumor suppressive gene 1)\(^3\). In various malignancies, reports of alterations in the p16\(^{\text{INK4A}}\) gene are much more common than those involving any other oncogene or tumor-suppressive gene ever identified\(^4\). It was particularly noticeable that there was no p16 expression in more than 70% of cell lines examined in the case of non-small cell lung cancer. It is speculated that p16\(^{\text{INK4A}}\) gene could exert a key role in the development of non-small cell lung cancer\(^1\). The purpose of this study was to investigate whether p16\(^{\text{INK4A}}\) gene is a suitable candidate for gene therapy in cases of non-small cell lung cancer. After the extraction of total RNA from normal fibroblast cell lines and subsequent reverse transcriptase and polymerase chain reaction, amplified p16\(^{\text{INK4A}}\) was subcloned into eukaryotic expression plasmid vector, pRC-CMV. Using lipofectin, the constructed pRC-CMV-p16 was transfected into NSCLC cell lines NCI-H441 and NCI-H357. After the extraction of proteins from cell lysates, the changes in G1...
cell-cycle related proteins were investigated with Western blot analysis and immunoprecipitation and the tumor suppressive effect was observed by clonogenic assay.

MATERIALS AND METHODS

Cell lines

Non-small cell lung cancer cell lines NCI-H441, NCI-H157 and NCI-H2009 were kindly donated by Frederic Kaye (National Cancer Institute, U.S.A.) and were grown in RPMI media supplemented with 10% fetal bovine serum and antibiotics. They were maintained at 37°C in a 5% CO₂ incubator and the media was changed twice a week.

Construction of p16 expression plasmid

p16 expression plasmid(pRC-CMV-p16) was kindly donated by Dr. Gregory Otterson (National Cancer Institute, U.S.A.). For the construction of p16 expression plasmid, RT-PCR was performed using mRNA from NIH3T3 fibroblast cell line (sense primer; 5’ AAG-CTT-ATG-GAG-CCT-TCG-GCT 3’, anti-sense primer; 5’ TTC-GAA-TCA-ATC-GGG-GAT-GTC 3’), and p16 cDNA was made. The length of p16 cDNA was 8 amino acids shorter than the natural full length. The PCR product was cloned into pRC-CMV plasmid, and the sequence was verified by sequencing. Using the cesium chloride method, an adequate quantity of pRC-CMV-p16 plasmid was obtained.

Transfection

Lung cancer cell lines, NCI-H441 and NCI-H157, were transfected via lipofectin, as described by the manufacturer (Life Technologies). Ten micrograms of pRC-CMV-p16 or control pRC-CMV plasmid were transfected into 100-mm diameter subconfluent plates.

Western blot analysis and Immunoprecipitation

Cellular protein was extracted 60 hours after transfection by lysing cells with lysis buffer50 mM Tris-HCl, pH 7.5/250 mM NaCl/5 mM EDTA/0.1% Nonidet P-40(NP-40)/50 mM NaF/1 mM phenylmethylsulfonyl fluoride (PMSF) containing protease inhibitors(10 ug/ml leupeptin and 50 ug/ml aprotonin). The lysate was incubated for 20 min on ice and was centrifuged(14,000 X g for 20 min); the supernatant was frozen at -70°C until used.

For Western blot analysis, 200 ug of cellular proteins were electroblotted to nitrocellulose paper after separation on 7.5 - 15 % SDS-PAGE and then allowed to incubate overnight at 4°C with a 1:2000 dilution of primary antibody(anti-human RB, p16, cdk4 or cyclin D1) in PBS containing 5% powdered milk and 1% bovine serum albumin. Conjugation with secondary antibodies and visualization was performed using an ECL kit(Amersham) as recommended by the manufacturer.

For immunoprecipitation, 500 ug of cellular proteins were immunoprecipitated with 10 ug of anti-human CDK4 or anti-human cyclin D1 antibodies. The immunoprecipitated proteins, separated by protein A-sepharose beads, were immunoblotted with anti-human p16 or anti-human RB antibodies.

Antibodies used for Western blot analysis and immunoprecipitation were mouse monoclonal anti-human RB, mouse monoclonal anti-human cyclin D1, rabbit polyclonal CDK4 and rabbit polyclonal anti-human p16(PharMingen, San Diego).

Clonogenic assay

After transfection, transfected cells were selected using G418(150 ug/ml) containing media. When visible colonies were seen, the plates were fixed with methanol and stained with crystal violet, and the numbers of colonies were compared.

RESULTS

Expression of p16 protein in transfected cells

Transfection of pRC-CMV-p16 to p16(-) NCI-H441 cells resulted in p16 expression equal to that seen in non-transfected NCI-H2009, which expresses p16 normally(Fig. 1). Control NCI-H441 cells did not express p16 protein(Fig. 1), and this indicates that in non-small cell lung cancer cell lines, the pRC-CMV-p16 expression vector is very useful for transfection.

p16:cdk4 complex formation of expressed p16 after transfection with pRC-CMV-p16

p16 protein, expressed in NCI-H441 cells after transfection with pRC-CMV-p16, formed a complex with cdk4(Fig. 2). p16 is known to inhibit cdk4 by forming a
THE EFFECTS OF TRANSFERRING TUMOR SUPPRESSOR GENE p16
IN K4A-DELETED CANCER CELLS

complex with it and inhibiting the phosphorylation of cdk4
substrate. The fact that p16 protein expressed after
transfection formed this complex indicates that p16
functioned normally.

De-phosphorylation of pRB protein after transfection
with pRC-CMV-p16

To determine the effect of p16 protein expressed after
transfection, changes in pRB protein in NCI-H441 cells
were investigated. As expected, the amount of
phosphorylated pRB protein was less than the amount of
phosphorylated pRB protein in control cells (Fig. 3). This
means that p16 protein expressed after transfection of
pRC-CMV-p16 inhibited the phosphorylation of pRB
protein by cdk4.

Changes in cyclin D1 and cyclin D1:cdk4 complex
after transfection with pRC-CMV-p16

Because p16 protein expressed after transfection
inhibited the phosphorylation of pRB, we investigated
changes in cyclin D1 and cyclin D1:cdk4 complex, known
to be involved in the phosphorylation of pRB. No
significant change was apparent in cyclin D1. However,
the change in cyclin D1:cdk4 complex could not be
determined because baseline cyclin D1:cdk4 complex
band was too faint in our experiment (Fig. 4).

Change in the pRB:cyclin D1 complex after
transfection with pRC-CMV-p16

In vivo, cyclin D1 is known to form a complex with
pRB, thus affecting the phosphorylation of pRB. After
transfection, no change in the pRB:cyclin D1 complex
was noted (Fig. 5), suggesting that p16 does not function
through change in the pRB:cyclin D1 complex.

Tumor suppressive effect of p16

The colony-forming ability of NCI-H441 and NCI-H157
cell lines after transfection with pRC-CMV-p16 was compared with that of control cell lines transfected with pRC-CMV. Significantly fewer colonies were observed in plates transfected with pRC-CMV-p16 than in those transfected with pRC-CMV (Fig. 6), and this suggests that p16 may have a tumor suppressive effect on non-small cell lung cancer cell lines which do not express p16.

**DISCUSSION**

A variety of evidence suggests that p16 is a tumor suppressor gene. p16<sup>INK4A</sup> is located in chromosome 9p21, where deletions have frequently been found in carcinomas of lung, kidney, ovary, pancreas, breast, bladder, head and neck and esophagus and in several other tumors, such as glioma, melanoma, leukemia and osteogenic sarcoma. In addition, homozygous deletions or mutations of the p16<sup>INK4A</sup> gene are also frequently observed in cell lines from these tumors. Because deletion or mutation of p16<sup>INK4A</sup> is significantly less frequent in primary cancer tissues than in cancer
cell lines, it has been suspected, however, that p16 may not be a true tumor suppressor gene\textsuperscript{(11)}. In cases of non-small cell lung cancer, about 70\% of cell lines do not express p16 protein\textsuperscript{11}, but mutation of the p16 gene is not frequent in primary tissues\textsuperscript{(11)}.

To confirm the tumor suppressive effect and the mechanisms of p16 gene in non-small cell lung cancer, we transfected p16\textsuperscript{645} gene into cell lines of this cancer via lipofectin. p16(-) NCI-H441 cell line transfected with pRC-CMV-p16 showed the formation of p16:cdk4 complex and decreased phosphorylated Rb protein, while the control cell line did not. These results are consistent with those of Sandig et al.\textsuperscript{12, 13}, who studied the expression of pRB in a hepatocellular carcinoma cell line\textsuperscript{14}, pRB has been shown to play a protective role in cell apoptosis\textsuperscript{(14)}. When its levels are sufficiently reduced, this role can no longer be maintained, and this may explain part of the tumor suppressor function of p16. Clonogenic assay demonstrated that the extent of colony formation was significantly less in p16(-) NCI-H441 and NCI-H157 cell lines transfected with pRC-CMV-p16 than in the control cell line. This study shows that the expression of p16 protein in gene-transfected NSCLC cell lines, in which p16 is absent, leads to p16:cdk4 complex formation and a subsequent decrease in phosphorylated pRB protein levels, and leads ultimately to tumor suppressive effects.

Using pRC/CMV plasmid vector, Okamoto et al.\textsuperscript{15} showed that when p16 gene transfer was involved, colony formation by esophageal cancer cell lines decreased\textsuperscript{(15)}. Arap et al.\textsuperscript{16, 17} demonstrated the growth suppressive effect of p16\textsuperscript{645} gene in p16(-) glioma cell lines\textsuperscript{(17)}, and this finding is in agreement with those of other reports\textsuperscript{18, 19}. Though this effect was not observed in glioma cell lines which express wild-type p16 protein\textsuperscript{18}. It has been suggested that CDK4 or cyclinD may be amplified or overexpressed\textsuperscript{18, 19}, or a G1/S cell cycle pathway such as p53-p21\textsuperscript{18, 19} may be inactivated in cases of glioma with wild-type p16 expression\textsuperscript{19}. This suggests that, for the general use of gene therapy for the treatment of cancer, combination gene therapy involving p53 and p16, for example, may be necessary.

Tumor suppressor gene therapy requires efficient delivery of therapeutic genes and a high level of expression of the newly transduced gene in the tumor. The adenovirus is an efficient expression vector that can be produced in high titers\textsuperscript{20}. Its expression time in the host cell is short, and it is thus suitable for use in gene replacement strategies involved in cancer treatment. For the clinical trial of p16 in cancer gene therapy, adenovirus vector is one of the suitable candidates. A few in vitro and animal studies on p16 in the adenovirus vector have been published recently\textsuperscript{21, 22}.

It was difficult to obtain cell lines in which the expression of p16 protein after transfection of p16\textsuperscript{645} gene in NSCLC cell lines was stable. Because p16-transfected cells which overexpress p16 do not usually survive, we could not obtain data relating to flow cytometric cell cycle analysis or quantitative cytotoxicity tests. This difficulty is a common problem in the study of tumor suppressor genes and, to overcome it, an inducible promoter is usually used in the cloning of expression vectors.

In this study, we confirmed in vitro that after transfection of p16\textsuperscript{645} gene to a cell line which has wild-type pRB but does not express p16, p16 formed a complex with cdk4, phosphorylation of pRB decreased, and there was decreased colony formation. This suggests that the p16\textsuperscript{645} gene can be a candidate for gene therapy in cases of NSCLC in which p16\textsuperscript{645} gene is inactivated.

REFERENCES

1. Kamb A, Gnis NA, Weaver-Feldhaus J, Liu Q, Hashman K, Tavigian SV, Stochert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-439, 1994
2. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gnis NA, Ding W, Hassey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Arkin JD, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JI, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene(CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus, Nature Genet 8:23-26, 1994
3. Nobori T, Munz K, Wu DJ, Lois A, Takabayashi K, Canon DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature 368: 753-756, 1994
4. Spnuck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumors, Nature 370: R33-34, 1994
5. Caims P, Muo L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Ret P, Blagundr NJE, Sf里面也有空格。水流也由。, D: Rates of p16(MTS 1) mutations in primary tumors with 9p loss. Science 265: 85-86, 1994
6. Otterson GA, Kitzke RA, Coxon A, Kim YW, Kaye FJ:
Absence of p16
IN K4 protein is restricted to the subset of lung cancer cell lines that retain wild-type RB. Oncogene 9:3375-3378, 1994

7. Peter M, Herskowitz I: Joining the complex: cyclin-dependent kinase inhibition proteins and the cell cycle. Cell 79:181-184, 1994

8. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDKI gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994

9. Caldas C, Hahn SA, da Costa LT, Redston MS, Schulte M, Seymour AB, Weinstein CL, Huban RH, Yeo CJ, Kim SE: Frequent somatic mutations and homozygous deletions of the p16/MTS1 gene in pancreatic adenocarcinoma. Nature Genet 8:27-32, 1994

10. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Misunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994

11. Xu L, Sgroi D,Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V: Mutational analysis of CDKN2 (MTS1/INK4a) in human breast carcinoma. Cancer Res 54:5262-5264, 1994

12. Okamoto A, Demetrick DJ, Spillane EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC: Mutations and altered expression of p16/INK4 in human cancer. Proc Natl Acad Sci USA 91:13045-13049, 1994

13. Sandig V, Brand K, Herwig S, et al: Adenovirally transferred p16/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 3(3):313-319, 1997

14. Haas-Kogan DA, Kogan SC, Levi D, et al: Inhibition of apoptosis by the retinoblastoma gene product. EMBO J. 14(3):461-472, 1995

15. Arap W, Nishikawa R, Fumari FB, Cavenee WK, Huang HS: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351-1354, 1995

16. Jin X, Nguyen D, Zhang WW, et al: Cell cycle arrest and inhibition of tumor cell proliferation by the p16/CDKN2 gene mediated by an adenovirus vector. Cancer Res. 55:5250-5253, 1995

17. Schump DS, Chen GA, Consoli U, et al: Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16/INK4. Cancer Gene Ther. 3(6):575-364, 1996

18. Reifenberger G, Reifenberger J, Ichimura K, Mietzner TS, Collins VP: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299-4303, 1994

19. He J, Collins VP, Al-Ahmadie-H Turner MF, Godbout R, Day RS, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807, 1994

20. Brody SL, Crystal RG: Adenovirus-Mediated In Vivo Gene Transfer. Ann N Y Acad Sci. 716:90-101, 1994

21. Fueyo J, Gomez-Manzano C, Yung WKA, et al: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 1996; 12:833-840.